RxDoctor Payments Data

Husain Rasheed, MD

Hematology & Oncology · Mount Vernon, OHNPI 1437144029

Payments from drug & device makers

$12,012in general payments, 2019–2025

Across 627 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$1K
  • Merck$1K
  • Pfizer$843
  • Amgen$750
  • AstraZeneca$739
  • Genentech USA, Inc.$566
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$11,49996%
  • Education$5134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,012 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$77,558
Medicare patients
280
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide58$904,448
CalquenceAcalabrutinib Maleate24$370,877
TabrectaCapmatinib Hydrochloride11$282,538
TasignaNilotinib Hcl11$255,948
VerzenioAbemaciclib14$208,692
RevlimidLenalidomide14$181,728
VenclextaVenetoclax16$180,075
Abiraterone Acetate57$157,120
Imatinib Mesylate24$116,307
BrukinsaZanubrutinib11$90,579
EliquisApixaban93$58,557
Anastrozole125$2,406
Mycophenolate Mofetil13$2,296
Ondansetron Hcl125$1,396
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$263$904,44858 claims
NovartisTabrecta, Tasigna$329$538,48622 claims
AstraZenecaCalquence$739$370,87724 claims
Lilly USA, LLCVerzenio$186$208,69214 claims
Bristol Myers SquibbRevlimid$266$181,72814 claims
AbbVieVenclexta$203$180,07516 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$37$157,12057 claims
Beigene USA, Inc.Brukinsa$45$90,57911 claims
PfizerEliquis$843$58,55793 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Mount Vernon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →